
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SELENIOUS ACID INJECTION safely and effectively. See full prescribing information for SELENIOUS ACID INJECTION.							
SELENIOUS ACID INJECTION, for intravenous use Initial U.S. Approval: 2019							
RECENT MAJOR CHANGES Dosage and Administration, Preparation Instructions for Admixing Using a Parenteral Nutrition Container (2.3) 10/2020 Recommended Dosage and Monitoring in Adult and Pediatric Patients (2.5) 8/2021 INDICATIONS AND USAGE							
Selenious Acid Injectionis a trace element indicated in adult and pediatric patients as a source of selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. (1)							
DOSAGE AND ADMINISTRATION							
 Pharmacy Bulk Package or Single-Dose Vial: Not for direct intravenous infusion. (2.1) See full prescribing information for information on preparation, administration, and general dosing considerations. (2.1, 2.2, 2.3, 2.4) Recommended Dosage (2.5) 							
 Selenious Acid Injection provides 60 mcg/mL of selenium. Selenious Acid Injection in a concentration of 6 mcg/mL is recommended for use in pediatric patients, particularly those weighing 7 kg or less. Individualize the dosage based upon the patient's clinical condition, nutritional requirements, and the 							
contribution of oral or enteral selenium intake. The following dosages are general recommendations intended for most patients. However, based upon clinical requirements, some patients may require a higher dosage:							
 Adults: 60 mcg/day Pediatric Patients 7 kg and above: 2 mcg/kg/day (up to 60 mcg/day) Pediatric Patients less than 7 kg: 2 to 4 mcg/kg/day Monitor selenium concentrations during treatment. 							
 Selenious Acid Injection, USP: (3) Pharmacy Bulk Package: 600 mcg/10 mL (60 mcg/mL) of selenium Single-Dose Vial: 12 mcg/2 mL (6 mcg/mL) of selenium 							
None. (4) WARNINGS AND PRECAUTIONS							
• <u>Pulmonary Embolism due to Pulmonary Vascular Precipitates</u> : If signs of pulmonary distress occur, stop the infusion and initiate a medical evaluation. (5.1)							
 <u>Vein Damage and Thrombosis:</u> Solutions with osmolarity of 900 mOsmol/L or more must be infused through a central venous catheter. (2.1, 5.2) <u>Aluminum Toxicity</u>: Increased risk in patients with renal impairment, including preterm infants. (5.3, 5.4) 							
 <u>Monitoring and Laboratory Tests</u>: Monitor selenium concentrations, fluid and electrolyte status, serum osmolarity, blood glucose, liver and kidney function, blood count and coagulation parameters throughout treatment. (5.4, 2.4) 							
ADVERSE REACTIONS							
No selenium-related adverse reactions in patients receiving intravenously administered parenteral nutrition solutions containing selenious acid within the recommended dosage range. (6)							

To report SUSPECTED ADVERSE REACTIONS, contact American Regent Inc. at 1-800-734-9236 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

FULL PRESCRIBING INFORMATION: CONTENTS* RECENT MAJOR CHANGES

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

- 2.1 Important Administration Information
- 2.2 Preparation and Administration Instructions
- 2.3 Preparation Instructions for Admixing Using a Parenteral Nutrition Container
- 2.4 Dosing Considerations
- 2.5 Recommended Dosage and Monitoring in Adults and Pediatric Patients

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Pulmonary Embolism due to Pulmonary Vascular Precipitates
- 5.2 Vein Damage and Thrombosis
- 5.3 Aluminum Toxicity
- 5.4 Monitoring and Laboratory Tests

6 ADVERSE REACTIONS

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Lactation
- 8.4 Pediatric Use
- 8.5 Geriatric Use

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

16 HOW SUPPLIED

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

Selenious Acid Injection is indicated in adult and pediatric patients as a source of selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.

2 DOSAGE AND ADMINISTRATION

2.1 Important Administration Information

Selenious Acid Injection is supplied as a pharmacy bulk package or single-dose vial for *admixing use* only. It is *not for direct intravenous infusion*. Prior to administration, Selenious Acid Injection*must be transferred to a separate parenteral nutrition container, prepared* and used as an admixture in parenteral nutrition solutions.

The Pharmacy Bulk Package vial of Selenious Acid Injection is intended for dispensing of single doses to multiple patients in a pharmacy admixture program.

The final parenteral nutrition solution is for intravenous infusion into a central or peripheral vein. The choice of a central or peripheral venous route should depend on the osmolarity of the final infusate. Solutions with osmolarity of 900 mOsmol/L or greater must be infused through a central venous catheter [see Warnings and Precautions (5.2)].

2.2 Preparation and Administration Instructions

• Selenious Acid Injection is *not for direct intravenous infusion*. Prior to administration, Selenious Acid Injection *must be prepared and used as an admixture* inparenteral nutrition *solutions*.

• Selenious Acid Injection is to be prepared only in a suitable work area such as a laminar flow hood (or an equivalent clean air compounding area). The key factor in the preparation is careful aseptic technique to avoid inadvertent touch contamination during mixing of solutions and addition of other nutrients.

• Visually inspect the prepared parenteral nutrition solution containing Selenious Acid Injection for particulate matter before admixing, after admixing, and prior to administration.

2.3 Preparation Instructions for Admixing Using a Parenteral Nutrition Container

- Inspect Selenious Acid Injection vials for particulate matter.
- Transfer Selenious Acid Injection to the parenteral nutrition solution following the admixture of amino acids, dextrose, lipid (if added), and electrolytes solutions.
- Because additives may be incompatible, evaluate all additions to the parenteral nutrition container for compatibility and stability of the resulting preparation. Consult with pharmacist, if available. Questions about compatibility may be directed to America Regent. If it is deemed advisable to introduce additives to the parenteral nutrition container, use aseptic technique.
- Inspect the final parenteral nutrition containing Selenious Acid Injection to ensure that:
 - Precipitates have not formed during mixing or addition of additives.
 - The admixed emulsion has not separated, if a lipid emulsion has been added. Separation of the admixed emulsion can be visibly identified by a yellowish streaking of the accumulation of yellowish droplets.
- Discard if any precipitates are observed.

Stability and Storage

- Single-dose vial (2 mL): Discard unused portion.
- Pharmacy Bulk Package vial (10 mL): Penetrate vial closure only one time with a suitable sterile transfer device or dispensing set that allows measured dispensing of the content.
- Use Selenious Acid Injection for admixing promptly once the sterile transfer set has been inserted into the Pharmacy Bulk Package container or not more than 4 hours at room temperature (25°C/77°F) after the container closure has been penetrated. Discard any remaining drug.
- Use parenteral nutrition solutions containing Selenious Acid Injection promptly after mixing. Any storage of the admixture should be under refrigeration from 2°C to 8°C (36°F to 46°F) and limited to a period of time no longer than 9 days. After removal from refrigeration, use promptly and complete the infusion within 24 hours. Discard any remaining admixture.
- Protect the admixed parenteral nutrition solution from light.

2.4 Dosing Considerations

- The dosage of the final parenteral nutrition containing Selenious Acid Injection must be based on the concentrations of all components in the solution and the recommended daily nutritional requirements [see Dosage and Administration (2.5)]. Consult the prescribing information of all added components to determine the recommended nutritional requirements for dextrose, amino acids and lipid emulsion, as applicable.
- Prior to administration of parenteral nutrition solution containing Selenious Acid Injection, correct severe fluid, electrolyte and acid-base disorders.

2.5 Recommended Dosage and Monitoring in Adults and Pediatric Patients

- There are two dosage strengths for Selenious Acid Injection: 6 mcg/mL and 60 mcg/mL of selenium.
- Selenious Acid Injection in a concentration of 6 mcg/mL is recommended for use in pediatric patients, particularly those weighing 7 kg or less.
- The dosage of Selenious Acid Injection should be individualized based on the patient's clinical condition, nutritional requirements, and the contribution of oral or enteral selenium intake.
- The dosages in Table 1 are general recommendations intended for most patients. However, based on clinical requirements, some patients may require a higher dosage.

Table 1: Recommended Dosage of Selenious Acid Injection for Adults andPediatric Patients by Estimated Weight

Population	Recommended Dosage
Adults	60 mcg/day
Pediatric Patients 7 kg and above	2 mcg/kg/day (up to 60 mcg/day)
Pediatric Patients less than 7 kg	2 to 4 mcg/kg/day

• Monitor selenium concentrations during treatment. Selenium concentrations may

vary depending on the assay used and the laboratory reference range.

3 DOSAGE FORMS AND STRENGTHS

Selenious Acid Injection, USP is a clear colorless solution available in the following:

- Pharmacy Bulk Package: 600 mcg/10mL (60 mcg/mL) of selenium
- Single-Dose Vial: 12 mcg/2 mL (6 mcg/mL) of selenium

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS

5.1 Pulmonary Embolism due to Pulmonary Vascular Precipitates

Pulmonary vascular precipitates causing pulmonary vascular emboli and pulmonary distress have been reported in patients receiving parenteral nutrition. The cause of precipitate formation has not been determined in all cases; however, in some fatal cases, pulmonary emboli occurred as a result of calcium phosphate precipitates. Precipitation has occurred following passage through an in-line filter; *in vivo* precipitate formation may also have occurred. If signs of pulmonary distress occur, stop the parenteral nutrition infusion and initiate a medical evaluation. In addition to inspection of the solution [see Dosage and Administration (2.2, 2.3)], the infusion set and catheter should also periodically be checked for precipitates.

5.2 Vein Damage and Thrombosis

Selenious Acid Injection has a low pH and must be prepared and used as an admixture in parenteral nutrition solutions. It is not for direct intravenous infusion.

In addition, consider the osmolarity of the final parenteral nutrition solution in determining peripheral versus central administration. Solutions with an osmolarity of 900 mOsmol/L or greater must be infused through a central catheter [see Dosage and Administration (2.1)]. The infusion of hypertonic nutrient injections into a peripheral vein may result in vein irritation, vein damage, and/or thrombosis. The primary complication of peripheral access is venous thrombophlebitis, which manifests as pain, erythema, tenderness or a palpable cord. Remove the catheter as soon as possible, if thrombophlebitis develops.

5.3 Aluminum Toxicity

Selenious Acid Injection contains aluminum that may be toxic.

Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Preterm infants are particularly at risk for aluminum toxicity because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which also contain aluminum.

Patients with impaired kidney function, including preterm neonates, who receive greater than 4 to 5 mcg/kg/day of parenteral aluminum can accumulate aluminum to levels

associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

Exposure to aluminum from Selenious Acid Injection is not more than 0.6 mcg/kg/day. When prescribing Selenious Acid Injection for use in parenteral nutrition containing other small volume parenteral products, the total daily patient exposure to aluminum from the admixture should be considered and maintained at no more than 5 mcg/kg/day [see Use in Specific Populations (8.4)].

5.4 Monitoring and Laboratory Tests

Monitor selenium concentrations, fluid and electrolyte status, serum osmolarity, blood glucose, liver and kidney function, blood count and coagulation parameters during treatment [see Dosage and Administration (2.5)].

6 ADVERSE REACTIONS

No selenium-related adverse reactions have been reported in clinical studies or postmarketing reports in patients receiving intravenously administered parenteral nutrition solutions containing selenious acid within the recommended dosage range.

The following adverse reactions associated with use of other components of parenteral nutrition solutions were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure:

- Pulmonary embolism due to pulmonary vascular precipitates [see Warnings and *Precautions (5.1)*]
- Vein damage and thrombosis [see Warnings and Precautions (5.2)]
- Aluminum toxicity [see Warnings and Precautions (5.3)]

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Administration of the recommended dose of Selenious Acid Injection in parenteral nutrition is not expected to cause major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted with intravenous selenious acid.

The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. n the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Clinical Considerations

Disease-associated Maternal and/or Embryo-Fetal Risk

Deficiency of trace elements, including selenium, is associated with adverse pregnancy

and fetal outcomes. Pregnant women have an increased metabolic demand for trace elements, including selenium. Parenteral nutrition with selenium should be considered if a pregnant woman's nutritional requirements cannot be fulfilled by oral or enteral intake.

8.2 Lactation

<u>Risk Summary</u>

Selenium is present in human milk. Administration of the approved recommended dose of Selenious Acid Injection in parenteral nutrition is not expected to cause harm to a breastfed infant. There is no information on the effects of selenious acid on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Selenious Acid Injection and any potential adverse effects on the breastfed infant from Selenious Acid Injection or from the underlying maternal condition.

8.4 Pediatric Use

Selenious Acid Injection is approved for use in the pediatric population, including neonates, as a source of selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. Safety and dosing recommendations in pediatric patients are based on clinical experience [see Dosage and Administration (2.5)].

Because of immature renal function, preterm infants receiving prolonged parenteral nutrition treatment with Selenious Acid Injection may be at higher risk of aluminum toxicity [see Warnings and Precautions (5.3)].

8.5 Geriatric Use

Reported clinical experience with intravenous selenious acid has not identified a difference in selenium requirements between elderly and younger patients. In general, dose selection should be individualized based on the patient's clinical condition, nutritional requirements, and additional nutritional intake provided orally or enterally to the patient.

10 OVERDOSAGE

There are no known cases of overdosage with intravenous selenious acid in parenteral nutrition.

Overdosage has been reported with oral selenium. Available selenium concentrations in these subjects have been reported using various assays and laboratory-based reference ranges over a period of time. Interpret results in the context of current reported ranges.

For oral selenium, the Tolerable Upper Limit (UL) is 400 mcg/day and the No Observed Adverse Effect Level (NOAEL) is 800 mcg/day. The estimated oral bioavailability of selenium is approximately 70%.

Acute Oral Toxicity Effects

Serious adverse events and deaths have been reported with acute oral toxicity, however, there is no clear correlation between the amount ingested, signs and symptoms of toxicity, or selenium blood concentrations.

With severe toxicity, the most common presenting symptoms within a few hours postingestion of oral doses greater than 1 gram/day of selenium are gastrointestinal (nausea, vomiting, diarrhea, and abdominal pain), altered mental status, and "garlic" breath odor.

Death from circulatory collapse has been reported after oral ingestion of 5 to 10 grams of selenium. Selenium serum or blood concentrations in fatal cases have been reported in the range of 190 mcg/dL to 3,800 mcg/dL.

Mild to moderate intoxication (myalgia, muscle spasms, and irritability) has been reported in patients with selenium serum or blood concentrations in the range of 41 to 750 mcg/dL.

Chronic Selenosis

Chronic daily exposure to selenium from dietary sources (0.003 to 0.007 grams/day) or oral supplements (0.0016 to 0.25 grams/day) may result in alopecia and nail brittleness. Other signs include gastrointestinal disturbances, skin rash, garlic breath, fatigue, irritability, and nervous system abnormalities including paresthesia and ataxia.

Selenium serum or blood concentrations in patients in China exposed through oral (nondietary) supplementation were in the range of 32 to 150 mcg/dL.

<u>Management</u>

There is no known antidote for acute selenium toxicity. Management of selenium overdosage is supportive care based on presenting signs and symptoms.

11 DESCRIPTION

Selenious Acid Injection, USP is a sterile, non-pyrogenic, clear, colorless solution intended for use as a trace element and additive to intravenous solutions for parenteral nutrition.

Each 600 mcg/10 mL Pharmacy Bulk Package vial contains 10 mL of selenious acid solution.

Each 6 mcg/mL single-dose vial contains 2 mL of selenious acid solution.

None of the presentations contain preservatives.


Each mL of the 60 mcg/mL strength contains 60 mcg of selenium present as 98 mcg of selenious acid, nitric acid for pH adjustment (1.8 to 2.4), and water for injection q.s.

Each mL of the 6 mcg/mL strength contains 6 mcg of selenium present as 9.8 mcg of selenious acid, nitric acid for pH adjustment (1.8 to 2.4), and water for injection q.s.

Selenious Acid Injection 60 mcg/mL contains no more than 2,500 mcg/L of aluminum and has a calculated osmolarity of 16 mOsmol/L.

Selenious Acid Injection 6 mcg/mL contains no more than 900 mcg/L of aluminum and has a calculated osmolarity of 13 mOsmol/L.

Selenious acid has a molecular weight of 128.97 g/mol and a formula of H_2SeO_3 . The structural formula is:



12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Selenious acid is converted *in vivo* to hydrogen selenide via glutathione-involved electron reductions. Hydrogen selenide acts as a selenium pool to form selenoproteins which include, but are not limited to, glutathione peroxidase, iodothyronine deiodinase, peroxidase and thioredoxins.

12.2 Pharmacodynamics

Selenious acid exposure-response relationships and the time course of pharmacodynamic responses is unknown.

12.3 Pharmacokinetics

Distribution

In humans 85% of intravenous administered ⁷⁵Se-sodium selenite was protein-bound within 4 to 6 hours and 95% by 24 hours.

<u>Elimination</u>

Selenium is primarily eliminated in urine.

16 HOW SUPPLIED

Selenious Acid Injection, USP is a clear, colorless solution available as:

- 600 mcg/10mL (60 mcg/mL) of selenium in a 10 mL pharmacy bulk package. Carton of 5 vials (NDC 0517-6560-05).
- 12 mcg/2 mL (6 mcg/mL) of selenium in a 2 mL single-dose vial. Carton of 10 vials (NDC 0517-6502-10).

The vial closure for both presentation is not made with natural rubber latex.

Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature]

For storage of admixed solution, see *Dosage and Administration (2.3)*.

17 PATIENT COUNSELING INFORMATION

Inform patients, caregivers or home healthcare providers of the following risks of Selenious Acid Injection:

- Pulmonary embolism due to pulmonary vascular precipitates [see Warnings and *Precautions (5.1)*]
- Vein damage and thrombosis [see Warnings and Precautions (5.2)]

• Aluminum toxicity [see Warnings and Precautions (5.3)]

AMERICAN

REGENT, INC. SHIRLEY, NY 11967

IN6560 Rev. 8/2021

PRINCIPAL DISPLAY PANEL - Container Label (10 mL)

NDC 0517-6560-01

Rx Only

Selenious Acid Injection, USP

600 mcg*/10 mL (60 mcg*/mL) of selenium

For intravenous use after dilution and admixing

PRESERVATIVE FREE

10 mL PHARMACY BULK PACKAGE



PRINICIPAL DISPLAY PANEL - Carton Labeling (10 mL)

NDC 0517-6560-05

Rx Only

Selenious Acid Injection, USP


600 mcg*/10 mL (60 mcg*/mL) of selenium

For intravenous use after dilution and admixing

STERILE. PRESERVATIVE FREE.

25 x 10 mL VIALS PHARMACY BULK PACKAGE

AMERICAN REGENT, INC. SHIRLEY, NY 11967



Serialization Label (10 mL)



PRINCIPAL DISPLAY PANEL - Container Label (2 mL)

NDC 0517-6502-01 Rx Only Selenious Acid Injection, USP 12 mcg*/2 mL (6 mcg*/mL) of selenium

For intravenous use after dilution and admixing

2 mL Single-Dose Vial



PRINCIPAL DISPLAY PANEL - Carton Labeling (2 mL)

NDC 0517-6502-10

Rx Only

Selenious Acid Injection, USP


12 mcg*/2 mL

(6 mcg*/mL) of selenium

For intravenous use after dilution and admixing

PRESERVATIVE FREE

10 X 2 mL Single-Dose Vials



Serialization Label (2 mL)



	ELENIOU lenious acid	S ACID injection, solut	ion				
Ρ	roduct Inf	ormation					
Ρ	roduct Type		HUMAN PRESCRIPTION DRUG	Item Code (Source) NDC:			NDC:0517-6560
Route of Administration			INTRAVENOUS				
A	ctive Ingre	dient/Active	Moiety				
Ingredient Name					Basis of S	Strength	Strength
SELENIUM (UNII: H6241UJ22B) (SELENIUM - UNII:H6241UJ22B)				SEL	ENIUM	60 ug in 1 mL	
Ir	nactive Ing	redients					
Ingredient Name Strength							Strength
w	ATER (UNII: 05	9QF0KO0R)					
NI	TRIC ACID (UN	NII: 411VRN1TV4)					
P	ackaging						
#	ltem Code	F	ackage Description	e Description Marketing Start Mar Date		Marketing End Date	
1	NDC:0517- 6560-05	5 in 1 BOX			07/01/201	.9	
1	NDC:0517- 6560-01	10 mL in 1 VIAL, I Combination Proc	PHARMACY BULK PACKAGE; Type 0: N duct	lot a			

Marketing	g Informa	tion			
Marketing Category	Applica	ation Number or Monograph Citation	Marketing Start Date	Marketing End Date	
NDA	NDA20937	9	07/01/2019		
SELENIOU					
elenious acid		Ition			
	injection, sole				
Product Info	ormation				
Product Type		HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0517-6502	
Route of Adm	inistration	INTRAVENOUS			
_					
Active Ingre					
	-	lient Name ELENIUM - UNII:H6241UJ22B)	Basis of Streng	th Strength 6 ug in 1 mL	
Inactive Ing	redients				
-		ngredient Name		Strength	
WATER (UNII: 05	9QF0KO0R)				
NITRIC ACID (UN	III: 411VRN1TV4)				
Packaging					
# Item Code	F	Package Description	Marketing Start Date	Marketing En Date	
1 NDC:0517- 6502-10	10 in 1 BOX		03/28/2022		
1 NDC:0517- 6502-01	2 mL in 1 VIAL Combination P	, SINGLE-DOSE; Type 0: Not a roduct			
Marketing	g Informa	tion			
Marketing Marketing Category		tion ation Number or Monograph Citation	Marketing Start Date	Marketing End Date	

Labeler - American Regent, Inc. (002033710)

Establishment						
Name	Address	ID/FEI	Business Operations			

Revised: 8/2021

American Regent, Inc.